Clover Corporation Limited Stock

Equities

CLV

AU000000CLV2

Food Processing

Delayed Australian S.E. 09:41:03 2024-06-13 pm EDT 5-day change 1st Jan Change
0.495 AUD -1.98% Intraday chart for Clover Corporation Limited -1.00% -40.00%
Sales 2024 * 64.64M 42.88M Sales 2025 * 75.37M 49.99M Capitalization 84.33M 55.94M
Net income 2024 * - 0 Net income 2025 * 3M 1.99M EV / Sales 2024 * 1.4 x
Net Debt 2024 * 5.98M 3.97M Net Debt 2025 * 2.48M 1.65M EV / Sales 2025 * 1.15 x
P/E ratio 2024 *
140 x
P/E ratio 2025 *
24.2 x
Employees -
Yield 2024 *
-
Yield 2025 *
1.65%
Free-Float 63.94%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Clover Corporation Limited

1 day+1.00%
1 week+2.02%
Current month+1.00%
1 month-0.98%
3 months-38.41%
6 months-37.27%
Current year-38.79%
More quotes
1 week
0.50
Extreme 0.495
0.51
1 month
0.50
Extreme 0.495
0.52
Current year
0.46
Extreme 0.46
0.85
1 year
0.46
Extreme 0.46
1.24
3 years
0.46
Extreme 0.46
1.90
5 years
0.46
Extreme 0.46
3.31
10 years
0.14
Extreme 0.14
3.31
More quotes
Managers TitleAgeSince
Chief Executive Officer - 14-11-10
Director of Finance/CFO - 21-05-05
Chief Operating Officer - -
Members of the board TitleAgeSince
Chairman - 15-06-30
Director/Board Member - 17-01-31
Director/Board Member 68 13-05-13
More insiders
Date Price Change Volume
24-06-13 0.495 -1.98% 112
24-06-13 0.505 +1.00% 39,203
24-06-12 0.5 0.00% 30,000
24-06-11 0.5 0.00% 25,779
24-06-07 0.5 0.00% 41,570

Delayed Quote Australian S.E., June 13, 2024 at 02:10 am EDT

More quotes
Clover Corporation Limited is focused on technology, new product development and commercialization. The principal activities of the Company are the refining and sale of natural oils, the production of encapsulated powders and the research and product development of functional food and infant nutrition ingredients. The Company’s microencapsulation technology enables nutritional oils, such as tuna, fish, algal and fungal oils, to be added to infant formula, foods, and beverages. Its technologies protect those sensitive oils from oxidation, allowing them to be incorporated into a range of applications. The Company, through its subsidiary, Nu-Mega Ingredients Pty Limited (Nu-Mega), supplies refined Omega-3 oils and a range of other encapsulated ingredients for use in infant formula, nutraceuticals, pharmaceuticals, and sports nutrition markets. Nu-Mega’s Driphorm range of microencapsulated powders enables the addition of Hi-DHA tuna and/or algal oils to a broad spectrum of products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.505 AUD
Average target price
0.6 AUD
Spread / Average Target
+18.81%
Consensus

Annual profits - Rate of surprise